Sun exec: Generic firms will face same tough times as innovators

High-flying Indian generics-maker Sun Pharmaceutical says it expects copycat companies to find themselves in the same uncomfortable position as cliff-hanging drug innovators are today beginning in 2015. Prepare for a struggle as fewer new treatments hit the market with their patent clocks ticking, says Sun chairman and managing director Dilip Shanghvi. His guidance: Copy what innovator drug companies do, not just what they make. Story

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.